SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

Citation
Zannad F, Ferreira JP, Pocock SJ, et al. Lancet 2020;396:819–29.